" class="no-js "lang="en-US"> Flagship Pioneering - Medtech Alert
Friday, March 29, 2024
Flagship Pioneering | Pharmtech Focus

Flagship Pioneering

About Flagship Pioneering

Flagship Pioneering

Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has applied a unique, hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $30 billion in aggregate value. To date, Flagship is backed by >$3 billion of aggregate capital commitments, of which over $1.5 billion has been deployed toward the founding and growth of its pioneering companies alongside >$10 billion of follow-on investments from other institutions. The current Flagship ecosystem includes Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Moderna Therapeutics (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Seres Therapeutics (NASDAQ: MCRB), and Syros Pharmaceuticals (NASDAQ: SYRS).

Related Story

Flagship Pioneering Unveils Laronde to Advance Endless RNA™

May 11 2021

Flagship Pioneering today unveiled Laronde, a platform company developing Endless RNA™ (eRNA), a novel, engineered […]

Omega Therapeutics to Advance Pipeline and Platform Development with Additional Financing

March 30 2021

Omega Therapeutics, Inc. (“Omega“), a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to […]